Remsima® tiene las mismas indicaciones que el fármaco biológico de referencia.1 Remsima es una molécula grande y su proceso de fabricación es complejo.

  • Enfermedad de Crohn en adultos.
  • Enfermedad de Crohn en pacientes pediátricos.
  • Colitis ulcerosa en adultos.
  • Colitis ulcerosa en pacientes pediátricos.
  • Artritis reumatoide
  • Espondilitis anquilosante
  • Artritis psoriásica
  • Psoriasis


1. European Medicines Agency. Committee for products for Human Use (CHMP). Assessment report: Remsima® (infliximab); June 2013. 2. Ficha técnica de Remsima®. 3. Park W,Hrycaj P, Jeka S, et al. A randomized, double-blind, parallel group, phase I study comparing the pharmacokinetics, safety and efficacy of CT-P13 and infliximab in patients with active ankylosing spondyiltis: 54-week results from the PLANETAS study. Poster presented at EULAR 2013, Madrid, 12–15 June. 4. Yoo DH, Hrycaj P, Miranda P, et al. Equivalence study comparing CT-P13 with infliximab in active RA. A Phase III, randomized controlled trial to compare CT-P13 with Infliximab (INX) in patients with active rheumatoid arthritis (RA): 54 week results from the PLANETRA STUDY. Presented at EULAR Annual Conference 2012, Messe Berlin, Berlin, Germany Abstract Session B4: Spondyloarthritis-Clinical aspects and treatment.

Share on FacebookShare on Google+Tweet about this on Twitter